PDS Biotechnology Corp — Director's Dealing 2017

Mar 15, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2017-03-13

Reporting Person: Macdonald R. Loch (Director, Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-13	Stock Option (right To Purchase)	$8.86	A	110000	Acquired	2027-03-13	Common Stock (110000)	Direct

Footnotes

F1: This option, representing a right to purchase a total of 110,000 shares of Common Stock, will become exercisable on February 17, 2018, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.